Loading…
Loading…
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md. , May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co.
/PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) en Boehringer Ingelheim hebben vandaag een licentie- en samenwerkingsovereenkomst
/PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to
/PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million Ingelheim, Germany, and Shanghai, China, 26, January 2026 - Boehringer Ingelheim and Simcere Pharmaceutical Group Ltd.
Ipsen obtient les droits mondiaux exclusifs, en dehors de la Grande Chine, pour le développement, la fabrication et la commercialisation de SIM0613, un conjugué anticorps-médicament ciblant le récepteur LRRC15. SIM0613 est conçu de manière optimale pour une pénétration intra-tumorale supérieure, étayée par des données d'efficacité précliniques probantes.
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy data Program expected to enter Phase I clinical development in H2 2026 Simcere Zaiming is eligible to receive up to $1.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for 2096.HK and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.